Abstract
Background Recognition of donor antigens by the recipient’s immune system leads to allograft rejection. HLA evolutionary divergence (HED) between an individual’s HLA alleles is a continuous metric that quantifies the differences between each amino acid of two homologous alleles and reflects the breadth of the immunopeptidome presented to T lymphocytes. We investigated whether or not HED of the donor or of the recipient has an impact on liver transplant rejection.
Method We did a retrospective cohort study in 1154 adult and 113 children recipients of liver transplant. We considered the histological lesions in liver biopsies performed routinely 1,2 and 5 years after transplantation and in case of liver dysfunction. Donor-specific anti-HLA antibodies (DSA) were determined in children at the time of biopsy. HED was calculated using the physicochemical Grantham distance for class I (HLA-A, HLA-B) and class II (HLA-DRB1, HLA-DQB1) alleles. We assessed the incidence of rejection-related liver lesions using a multivariate Cox proportional hazards regression analysis.
Findings In the adult cohort, recipients from donors with class I HED above the median had a higher risk of acute or chronic rejection, but not of other histological lesions. HED of the recipients was not related to any histological lesion. In multivariate analysis, a high donor class I HED was associated with acute rejection (hazard ratio [HR] 1.79; 95% confidence interval [CI]: 1.34-2.40; P<0.0001) or chronic rejection (HR 2.26, CI 1.45-3.51; P<0.0001) and was independent of age and HLA identities. In the pediatric cohort, class I HED of the donor was also associated with acute rejection (HR 1.81, 95% CI 1.12-3.14; P=0.013) independently of the presence of DSA.
Interpretation Class I HED of the donor reflects graft immunogenicity and predicts rejection independently of donor-recipient HLA compatibility. This novel and easily accessible prognostic marker could improve donor selection and guide immunosuppression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
APHP INSERM
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Commission nationale informatique liberte: CNIL Numero 1856085 Comite protection des personnes CCP Ile de France 7 Kremlin Bicetre CO 16-006
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding Assistance Publique-Hôpitaux de Paris, and Institut National de la Santé et de la Recherche Médicale (INSERM)
Data Availability
All the data are available
